New anesthetic may offer safer sedation for heart valve patients
NCT ID NCT05881291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new sedative called ciprofol against the standard drug propofol for general anesthesia in 124 older adults undergoing transcatheter aortic valve replacement (TAVR). The goal was to see if ciprofol causes fewer episodes of low blood pressure after anesthesia. Researchers measured blood pressure changes in the first 15 minutes after sedation and tracked side effects like injection pain.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ciprofol
- What this could lead to
- If successful, ciprofol could offer a safer alternative to propofol for anesthesia in heart valve replacement, with fewer drops in blood pressure.
- What could go wrong
- This is a small, completed phase 4 trial with 124 patients. Results may not apply to all patients, and ciprofol's benefits over propofol may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
124 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients planned for transfemoral transcatheter aortic valve replacement * expected duration of surgery ≥ 1 and ≤ 3h * patients undergoing general anesthesia * no gender limit，age≥60 years，≤85 years * BMI ≥18 and ≤30kg/m2 * ASA physical status 3\~4 * be able to understand the procedures and methods of the trial and voluntarily sign the informed consent form Exclusion Criteria: * predicted presence of difficult airway or previous history of difficult airway * allergic to eggs, soy products, propofol, and opioids and their antidotes * patients with shock or hypotension that is difficult to correct with vasopressor * patients with mental, nervous system diseases, long-term use of sedatives or antidepressants * HB \< 10.0 g/dL (100 g/L) * patients with previous long-term use of sedative and analgesic drugs * patients with severe heart，lung，liver and kidney disease * not suitable for participation in this study as assessed by the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Zhejiang University anesthesiology department
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Muscle relaxant dose may hold key to better breathing tube alternative
- The 3 AM intubation: does fatigue make airway management more dangerous?
- Can aggressive blood pressure treatment slow aortic valve disease?
- Why do animal heart valves wear out? immune system under investigation
- 24 sensors map muscle oxygen after ACL surgery
- One scan to rule them all? new CT aims to replace multiple heart tests